The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy

被引：62

作者：

Kumar S.K.S. ^{[1
]}

Gorur A. ^{[2
]}

Schaudinn C. ^{[2
]}

Shuler C.F. ^{[3
]}

Costerton J.W. ^{[4
]}

Sedghizadeh P.P. ^{[5
]}

机构：

[1] Clinical Dentistry, Orofacial Pain and Oral Medicine Center, School of Dentistry, University of Southern California, Los Angeles, CA

[2] Center for Biofilms, School of Dentistry, University of Southern California, Los Angeles, CA

[3] School of Dentistry, University of British Columbia, Vancouver, BC

[4] Department of Orthopedic Surgery, Allegheny General Hospital and Center for Genomics, Allegheny-Singer Research Institute, Pittsburgh, PA

[5] USC School of Dentistry, Center for Biofilms, Los Angeles, CA 90089-0641

来源：

Current Osteoporosis Reports | 2010年 / 8卷 / 1期

关键词：

Bisphosphonate; Bone; BONJ; Infection; Microcrack; Osteonecrosis;

D O I：

10.1007/s11914-010-0008-1

中图分类号：

学科分类号：

摘要：

Microbial biofilms have been observed and described in bone specimens of patients with bisphosphonate (BP)-associated osteonecrosis of the jaw (BONJ) and investigators are more recently suggesting that this condition essentially represents an osteomyelitis of the jaw clinically, with greater susceptibility in some patients on BP therapy. This article explains the role of microbial biofilms in BONJ and also discusses associated factors in the disease pathogenesis, which include BP effects on bone remodeling, anti-angiogenesis, matrix necrosis, microcracks, soft tissue toxicity, and inflammation and wound healing. Recent findings suggest a key role for microbial biofilms in the pathogenesis of BONJ; this has important therapeutic implications because biofilm organisms represent a clinical target for prevention and treatment efforts aimed at reducing the significant morbidity and costs associated with this condition. © Springer Science+Business Media, LLC 2010.

引用

页码：40 / 48

页数：8

共 53 条

[1]

Marx R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, pp. 1115-1117, (2003)

[2]

Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L., Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, pp. 527-534, (2004)

[3]

Reid I.R., Osteonecrosis of the jaw: Who gets it, and why?, Bone, 44, pp. 4-10, (2009)

[4]

Hansen T., Kunkel M., Weber A., James K.C., Osteonecrosis of the jaws in patients treated with bisphosphonates - Histomorphologic analysis in comparison with infected osteoradionecrosis, J Oral Pathol Med, 35, pp. 155-160, (2006)

[5]

Hansen T., Kunkel M., Springer E., Et al., Actinomycosis of the jaws - Histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis, Virchows Arch, 451, pp. 1009-1017, (2007)

[6]

Sedghizadeh P.P., Kumar S.K., Gorur A., Et al., Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy, J Oral Maxillofac Surg, 66, pp. 767-775, (2008)

[7]

Dunstan C.R., Felsenberg D., Seibel M.J., Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumorinduced bone disease, Nat Clin Pract Oncol, 4, pp. 42-55, (2007)

[8]

Weinstein R.S., Roberson P.K., Manolagas S.C., Giant osteoclast formation and long-term oral bisphosphonate therapy, N Engl J Med, 360, pp. 53-62, (2009)

[9]

Djulbegovic B., Wheatley K., Ross J., Et al., Bisphosphonates in multiple myeloma, Cochrane Database Syst Rev, 3, (2002)

[10]

Wells G.A., Cranney A., Peterson J., Et al., Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, 1, (2008)

← 1 2 3 4 5 6 →